Menu Search
Equities

Syndax Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1T3:STU

Syndax Pharmaceuticals Inc

Actions
  • Price (EUR)17.10
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+21.28%
  • Beta0.4355
Data delayed at least 15 minutes, as of Feb 17 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Syndax Pharmaceuticals Inc's net income fell 52.25% from a loss of 209.36m to a larger loss of 318.76m despite revenues that grew -- from 0.00 to 23.68m.
Gross margin95.44%
Net profit margin-279.31%
Operating margin-275.12%
Return on assets-63.74%
Return on equity-129.32%
Return on investment-77.50%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Syndax Pharmaceuticals Inc fell by 141.31m. Cash Flow from Financing totalled 353.37m or 1,492.26% of revenues. In addition the company used 274.90m for operations while cash used for investing totalled 219.78m.
Cash flow per share-3.61
Price/Cash flow per share--
Book value per share1.33
Tangible book value per share1.33
More ▼

Balance sheet in USDView more

Syndax Pharmaceuticals Inc has a Debt to Total Capital ratio of 74.87%, a higher figure than the previous year's 0.00%.
Current ratio4.64
Quick ratio4.42
Total debt/total equity2.98
Total debt/total capital0.7487
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.